| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.73B | 115.36B | 122.13B | 116.62B | 103.03B | 92.02B |
| Gross Profit | 26.73B | 25.42B | 25.98B | 26.58B | 23.45B | 21.24B |
| EBITDA | 10.82B | 11.75B | 13.40B | 15.80B | 11.48B | 14.35B |
| Net Income | 5.14B | 5.00B | 6.29B | 7.71B | 5.01B | 7.10B |
Balance Sheet | ||||||
| Total Assets | 122.96B | 119.73B | 118.01B | 114.65B | 99.70B | 96.25B |
| Cash, Cash Equivalents and Short-Term Investments | 34.59B | 30.93B | 25.23B | 33.16B | 29.40B | 32.74B |
| Total Debt | 879.00M | 1.11B | 2.09B | 3.53B | 4.93B | 4.89B |
| Total Liabilities | 43.68B | 43.36B | 43.63B | 43.50B | 35.87B | 34.71B |
| Stockholders Equity | 70.34B | 67.63B | 65.80B | 63.05B | 56.28B | 53.86B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 9.41B | 219.00M | 6.07B | 636.00M | 5.98B |
| Operating Cash Flow | 0.00 | 13.54B | 5.70B | 9.26B | 3.25B | 8.64B |
| Investing Cash Flow | 0.00 | -2.91B | -2.41B | -6.65B | -1.97B | -749.00M |
| Financing Cash Flow | 0.00 | -4.94B | -6.20B | -3.85B | -4.62B | -1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥89.85B | 16.74 | ― | 3.13% | 5.09% | 26.12% | |
76 Outperform | ¥193.15B | 18.58 | ― | 2.36% | 13.82% | 37.07% | |
75 Outperform | $139.40B | 10.17 | 11.52% | 2.90% | 4.00% | 38.72% | |
73 Outperform | ¥188.65B | 18.46 | ― | 2.08% | 9.29% | 1.18% | |
71 Outperform | ¥79.16B | 12.33 | ― | 3.29% | 5.28% | 28.90% | |
66 Neutral | ¥187.88B | 16.55 | 18.89% | 2.63% | 11.90% | 60.66% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
Mitsubishi Research Institute reported a strong financial performance for the fiscal year ended September 30, 2025, with significant increases in net sales, operating profit, and profit attributable to owners of the parent. The company experienced a notable improvement in comprehensive income, reflecting a robust recovery from the previous fiscal year. This financial growth positions Mitsubishi Research Institute favorably within its industry, potentially enhancing its market competitiveness and stakeholder confidence.
The most recent analyst rating on (JP:3636) stock is a Buy with a Yen5491.00 price target. To see the full list of analyst forecasts on Mitsubishi Research Institute stock, see the JP:3636 Stock Forecast page.